These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23114778)

  • 1. Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.
    Livermore JL; Felton TW; Abbott J; Sharp A; Goodwin J; Gregson L; Warn PA; Howard SJ; Hope WW
    Antimicrob Agents Chemother; 2013 Jan; 57(1):281-8. PubMed ID: 23114778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.
    Warn PA; Livermore J; Howard S; Felton TW; Sharp A; Gregson L; Goodwin J; Petraitiene R; Petraitis V; Cohen-Wolkowiez M; Walsh TJ; Benjamin DK; Hope WW
    Antimicrob Agents Chemother; 2012 Feb; 56(2):708-14. PubMed ID: 22123680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model.
    Karagoz E; Ugan RA; Duzgun E; Cadirci E; Keles S; Uyanik MH; Yavan I; Turhan V
    Curr Eye Res; 2017 Feb; 42(2):225-232. PubMed ID: 27348425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
    Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
    Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
    Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
    Andes D; Diekema DJ; Pfaller MA; Prince RA; Marchillo K; Ashbeck J; Hou J
    Antimicrob Agents Chemother; 2008 Feb; 52(2):539-50. PubMed ID: 18070979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.
    Mochizuki K; Suemori S; Udo K; Komori S; Ohkusu K; Yamada N; Ogura S
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):531-3. PubMed ID: 21751880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
    Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Hope WW; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
    Lepak AJ; Marchillo K; VanHecker J; Diekema D; Andes DR
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5642-8. PubMed ID: 24002092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
    Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
    Dupont H; Massias L; Jung B; Ammenouche N; Montravers P
    J Antimicrob Chemother; 2017 May; 72(5):1429-1432. PubMed ID: 28088767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of
    Petraitiene R; Petraitis V; Maung BBW; Mansbach RS; Hodges MR; Finkelman MA; Shaw KJ; Walsh TJ
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361304
    [No Abstract]   [Full Text] [Related]  

  • 14. In Vitro Susceptibilities of Vitreous Candida Endophthalmitis Isolates to Newer and Traditional Antifungal Agents.
    Fan KC; Russell JF; Miller D; Flynn HW
    Ophthalmic Surg Lasers Imaging Retina; 2019 May; 50(5):S13-S17. PubMed ID: 31100177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
    Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
    Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.
    Liu P
    Antimicrob Agents Chemother; 2013 Jan; 57(1):466-74. PubMed ID: 23129052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
    Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
    Breit SM; Hariprasad SM; Mieler WF; Shah GK; Mills MD; Grand MG
    Am J Ophthalmol; 2005 Jan; 139(1):135-40. PubMed ID: 15652837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.